Abstract: This disclosure provides multimeric binding molecules that specifically and agonistically bind to programmed cell death protein 1 (PD-1). This disclosure also provides compositions comprising the multimeric binding molecules, polynucleotides that encode the multimeric binding molecules, and host cells that can produce the binding molecules. Further this disclosure provides methods of using the multimeric binding molecules, including methods for treating autoimmune disorders and preventing transplantation rejection.

Abstract: This disclosure provides therapeutic methods for treating cancer including combination therapy with a multimeric anti-DR5 antibody and a cancer therapy, e.g., radiation, an anthracycline, a folic acid analog, a platinum-based agent, a taxane, a topoisomerase II inhibitor, a SMAC mimetic, a vinca alkaloid, a Brutons tyrosine kinase (BTK) inhibitor, a phosphoinositide 3-kinase delta (PI3K?) inhibitor, a myeloid cell leukemia-1 (Mcl-1) inhibitor, or any combination thereof.

Abstract: This disclosure provides multivalent, bispecific, anti-CD123 binding molecule comprising a modified J-chain that specifically binds to an immune effector cell. Also provided are polynucleotides encoding the binding molecule or subunits thereof and vectors and host cell comprising said polynucleotides. This disclosure further provides methods for producing and/or using a multivalent, bispecific, anti-CD123 binding molecule comprising a modified J-chain that specifically binds to an immune effector cell.

Abstract: Described herein are methods of treating cancer using combinations of Leukemia Inhibitory Factor (LIF)-binding polypeptides and platinum-based antineoplastic agents.